The Life Span of Patients with Primary (AL) Amyloidosis and the Effect of Colchicine Treatment
There is no specific treatment for any variety of amyloidosis . Primary (AL) amyloidosis, now the more commonly seen form of the disorder, usually has a poor prognosis and short life expectancy . Colchicine, which effectively prevents acute fibril attacks in patients with familial Mediterranean fever (FMF), a condition that predisposes to amyloidosis, has been shown to block amyloid production in the mouse model [3,4]. In addition, reports indicate that patients with FMF receiving colchicine no longer develop amyloidosis and suggest improvement in some amyloidotic patients with this form of AA amyloid [5, 6].
KeywordsFamilial Mediterranean Fever Colchicine Treatment Short Life Expectancy Cancer Treatment Report General Clinical Research Center
Unable to display preview. Download preview PDF.
- 5.D. Zemer, et al., in: Amyloid and Amyloidosis (G. G. Glenner, P. Costa, and F. Freitas, eds.), Excerpta Medica, pp. 584–586 (1980).Google Scholar
- 7.R. A. Kyle and E. D. Baird, Mayo Clin. Proc., 54:271 (1975).Google Scholar
- 12.A. S. Cohen et al., Revue de rhumatisme, XVth International Congress of Rheumatology, June 1981, p. 1171.Google Scholar
- 19.A. S. Cohen et al., Submitted for publication.Google Scholar